Lysophosphatidic acid (Oleyl form) |
|
Catalog No.GB40270
|
Lysophosphatidic acid (Oleyl form) est un lipide bioactif qui joue un rôle important dans la signalisation cellulaire et divers processus biologiques. Il peut agir en tant qu'un agoniste des récepteurs de Llysophosphatidic acid (LPA), affectant la croissance cellulaire, la migration et d'autres fonctions cellulaires.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 22556-62-3
Sample solution is provided at 25 µL, 10mM.
Lysophosphatidic acid (Oleyl form) est un lipide bioactif qui joue un rôle important dans la signalisation cellulaire et divers processus biologiques. Il peut agir en tant qu'un agoniste des récepteurs de Llysophosphatidic acid (LPA), affectant la croissance cellulaire, la migration et d'autres fonctions cellulaires[1, 2]. Lysophosphatidic acid est une molécule lipidique simple composée d'un groupe de tête phosphate ou phosphate cyclique (appelé phosphate cyclique), d'un squelette de glycérol et d'une chaîne d'acide gras ou d'alcool gras[3]. Lysophosphatidic acid est également un agoniste direct du récepteur activé par les proliférateurs de peroxysomes γ (PPARγ)[4]. Lysophosphatidic acid peut provoquer une inflammation, une thrombose et une athérosclérose[5]. Lysophosphatidic acid peut favoriser la polarisation de BV-2 et de la microglie primaire de rat vers un phénotype de type M1[6]. Lysophosphatidic acid administré par voie intra-péritonéale peut réduire significativement la lésion hépatique aiguë induite par l'acétaminophène (APAP) chez les rats[7].
References:
[1] Tigyi G, Parrill A L. Molecular mechanisms of lysophosphatidic acid action[J]. Progress in lipid research, 2003, 42(6): 498-526.
[2] Moolenaar W H. Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger[J]. Journal of Biological Chemistry, 1995, 270(22): 12949-12952.
[3] Liu W, Hopkins A M, Hou J. The development of modulators for lysophosphatidic acid receptors: A comprehensive review[J]. Bioorganic chemistry, 2021, 117: 105386.
[4] Geraldo L H M, Spohr T C L S, Amaral R F, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies[J]. Signal transduction and targeted therapy, 2021, 6(1): 45.
[5] Zhou Y, Little P J, Ta H T, et al. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease[J]. Pharmacology & Therapeutics, 2019, 204: 107404.
[6] Plastira I, Bernhart E, Goeritzer M, et al. 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype[J]. Journal of neuroinflammation, 2016, 13: 1-18.
[7] Bae G H, Lee S K, Kim H S, et al. Lysophosphatidic acid protects against acetaminophen-induced acute liver injury[J]. Experimental & molecular medicine, 2017, 49(12): e407-e407.
| Cas No. | 22556-62-3 | SDF | |
| Formula | C21H41O7P·xNa+ | M.Wt | 436.52 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2908 mL | 11.4542 mL | 22.9085 mL |
| 5 mM | 458.2 μL | 2.2908 mL | 4.5817 mL |
| 10 mM | 229.1 μL | 1.1454 mL | 2.2908 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















